AR045461A1 - Formulacion en polvo que contiene el antagonista de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1- piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piridinil)-piperazina, procedimiento para su preparacion y su uso como inhalador - Google Patents

Formulacion en polvo que contiene el antagonista de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1- piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piridinil)-piperazina, procedimiento para su preparacion y su uso como inhalador

Info

Publication number
AR045461A1
AR045461A1 ARP040102955A ARP040102955A AR045461A1 AR 045461 A1 AR045461 A1 AR 045461A1 AR P040102955 A ARP040102955 A AR P040102955A AR P040102955 A ARP040102955 A AR P040102955A AR 045461 A1 AR045461 A1 AR 045461A1
Authority
AR
Argentina
Prior art keywords
preparation
oxoquinazolin
dibromo
procedure
cgrp antagonist
Prior art date
Application number
ARP040102955A
Other languages
English (en)
Spanish (es)
Inventor
Michael Trunk
Claudius Weiler
Christel Schelmezer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR045461A1 publication Critical patent/AR045461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP040102955A 2003-08-18 2004-08-18 Formulacion en polvo que contiene el antagonista de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1- piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piridinil)-piperazina, procedimiento para su preparacion y su uso como inhalador AR045461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10338403A DE10338403A1 (de) 2003-08-18 2003-08-18 Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum

Publications (1)

Publication Number Publication Date
AR045461A1 true AR045461A1 (es) 2005-10-26

Family

ID=34201782

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102955A AR045461A1 (es) 2003-08-18 2004-08-18 Formulacion en polvo que contiene el antagonista de cgrp 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1- piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piridinil)-piperazina, procedimiento para su preparacion y su uso como inhalador

Country Status (7)

Country Link
EP (1) EP1660046A1 (enExample)
JP (1) JP2007502792A (enExample)
AR (1) AR045461A1 (enExample)
CA (1) CA2536053A1 (enExample)
DE (1) DE10338403A1 (enExample)
TW (1) TW200516077A (enExample)
WO (1) WO2005018614A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung

Also Published As

Publication number Publication date
TW200516077A (en) 2005-05-16
WO2005018614A1 (de) 2005-03-03
DE10338403A1 (de) 2005-03-17
EP1660046A1 (de) 2006-05-31
JP2007502792A (ja) 2007-02-15
CA2536053A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
WO2005018603A3 (de) Sprühgetrocknetes, amorphes bibn 4096, verfahren zu dessen herstellung sowie dessen verwendung als inhalativum
ITMI20051999A1 (it) Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
HUS1900056I1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
BRPI0413849A (pt) metanossulfonato de etiléster de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2 -il-amino]-propiÈnico e seu uso como medicamento
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
NZ604983A (en) Dry powder formulation comprising an antimuscarinic drug
ECSP10010265A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
EA201291421A1 (ru) Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
ECSP045367A (es) "derivados de bencimidazol utiles como antagonistas de histamina h3"
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
BR112014011981A2 (pt) formulações farmacêuticas
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
SE0402345D0 (sv) A metered medication dose
AR035253A1 (es) Composicion para la profilaxis, tratamiento o reduccion de las exacerbaciones asociadas con una enfermedad pulmonar y uso de una cantidad eficaz de un inhibidor de pde4 y una cantidad eficaz de un antagonista del receptor h1 para su fabricacion.
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
EP2323656A4 (en) PHARMACEUTICAL PRODUCT USING A MUSCARIN RECEPTOR ANTAGONIST AND A BETA-2 ADRENOZEPTORAGONIST
EP2315589A4 (en) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST
UY28474A1 (es) Formulación en polvo que contiene el antagonista de cgrp 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-piridinil)-piperazina, procedimiento para su preparación y su uso como inhalado
BRPI0409377A (pt) combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases

Legal Events

Date Code Title Description
FB Suspension of granting procedure